Research ExplorerPublicationsCytokine serum levels during post-transplant adverse events ...

Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation

Standard

Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation. / Döring, Michaela; Cabanillas Stanchi, Karin Melanie; Mezger, Markus; Erbacher, Annika; Feucht, Judith; Pfeiffer, Matthias; Lang, Peter; Handgretinger, Rupert; Müller, Ingo.

In: BMC CANCER, Vol. 15, 28.08.2015, p. Art. 607.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Transfer › peer-review

Harvard

Döring, M, Cabanillas Stanchi, KM, Mezger, M, Erbacher, A, Feucht, J, Pfeiffer, M, Lang, P, Handgretinger, R & Müller, I 2015, 'Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation', BMC CANCER, vol. 15, pp. Art. 607. https://doi.org/10.1186/s12885-015-1616-z

APA

Döring, M., Cabanillas Stanchi, K. M., Mezger, M., Erbacher, A., Feucht, J., Pfeiffer, M., Lang, P., Handgretinger, R., & Müller, I. (2015). Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation. BMC CANCER, 15, Art. 607. https://doi.org/10.1186/s12885-015-1616-z

Vancouver

Döring M, Cabanillas Stanchi KM, Mezger M, Erbacher A, Feucht J, Pfeiffer M et al. Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation. BMC CANCER. 2015 Aug 28;15:Art. 607. https://doi.org/10.1186/s12885-015-1616-z

Bibtex

@article{5e78e27fad7a4e4887db69f6e42b211f,
title = "Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation",
abstract = "BACKGROUND: Veno-occlusive disease, Graft-versus-Host disease, invasive or localized bacterial, viral and fungal infections are known as adverse events after hematopoietic stem cell transplantation representing the major cause for morbidity and mortality. Detection and differentiation of these adverse events are based on clinical symptoms and routine measurements of laboratory parameters.METHODS: To identify the role of cytokines as a possible complication-marker for adverse events, 61 consecutive pediatric patients with a median age of 7.0 years who underwent hematopoietic stem cell transplantation were enrolled in this single-center retrospective study. Interleukin-1 beta (IL-1β), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and tumor necrosis factor-α serum (TNF-α) levels were regularly assessed after transplantation and during transplantation related adverse events.RESULTS: Veno-occlusive disease was accompanied by a significant increase in levels of IL-6, IL-8 and TNF-α.Graft-versus-Host disease was associated with a significant increase of IL-10, sIL-2R, IL-6 and TNF-α, depending on the respective stage or grade. Cytokine IL-6 enabled a significant differentiation between sepsis and fungemia, sepsis and viremia, and sepsis and bacteremia. Moreover, cytokine IL-8 enabled a significant differentiation between sepsis and viremia, sepsis and bacteremia, and bacteremia and viremia whereas IL-10 made a distinction between sepsis and viremia possible.CONCLUSION: The data demonstrate that proinflammatory cytokines might be putative indicators for early detection and differentiation of post-transplant adverse events and may allow prompt and adequate clinical intervention. Prospective clinical trials are needed to evaluate these findings.",
author = "Michaela D{\"o}ring and {Cabanillas Stanchi}, {Karin Melanie} and Markus Mezger and Annika Erbacher and Judith Feucht and Matthias Pfeiffer and Peter Lang and Rupert Handgretinger and Ingo M{\"u}ller",
year = "2015",
month = aug,
day = "28",
doi = "10.1186/s12885-015-1616-z",
language = "English",
volume = "15",
pages = "Art. 607",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation

AU - Döring, Michaela

AU - Cabanillas Stanchi, Karin Melanie

AU - Mezger, Markus

AU - Erbacher, Annika

AU - Feucht, Judith

AU - Pfeiffer, Matthias

AU - Lang, Peter

AU - Handgretinger, Rupert

AU - Müller, Ingo

PY - 2015/8/28

Y1 - 2015/8/28

N2 - BACKGROUND: Veno-occlusive disease, Graft-versus-Host disease, invasive or localized bacterial, viral and fungal infections are known as adverse events after hematopoietic stem cell transplantation representing the major cause for morbidity and mortality. Detection and differentiation of these adverse events are based on clinical symptoms and routine measurements of laboratory parameters.METHODS: To identify the role of cytokines as a possible complication-marker for adverse events, 61 consecutive pediatric patients with a median age of 7.0 years who underwent hematopoietic stem cell transplantation were enrolled in this single-center retrospective study. Interleukin-1 beta (IL-1β), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and tumor necrosis factor-α serum (TNF-α) levels were regularly assessed after transplantation and during transplantation related adverse events.RESULTS: Veno-occlusive disease was accompanied by a significant increase in levels of IL-6, IL-8 and TNF-α.Graft-versus-Host disease was associated with a significant increase of IL-10, sIL-2R, IL-6 and TNF-α, depending on the respective stage or grade. Cytokine IL-6 enabled a significant differentiation between sepsis and fungemia, sepsis and viremia, and sepsis and bacteremia. Moreover, cytokine IL-8 enabled a significant differentiation between sepsis and viremia, sepsis and bacteremia, and bacteremia and viremia whereas IL-10 made a distinction between sepsis and viremia possible.CONCLUSION: The data demonstrate that proinflammatory cytokines might be putative indicators for early detection and differentiation of post-transplant adverse events and may allow prompt and adequate clinical intervention. Prospective clinical trials are needed to evaluate these findings.

AB - BACKGROUND: Veno-occlusive disease, Graft-versus-Host disease, invasive or localized bacterial, viral and fungal infections are known as adverse events after hematopoietic stem cell transplantation representing the major cause for morbidity and mortality. Detection and differentiation of these adverse events are based on clinical symptoms and routine measurements of laboratory parameters.METHODS: To identify the role of cytokines as a possible complication-marker for adverse events, 61 consecutive pediatric patients with a median age of 7.0 years who underwent hematopoietic stem cell transplantation were enrolled in this single-center retrospective study. Interleukin-1 beta (IL-1β), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and tumor necrosis factor-α serum (TNF-α) levels were regularly assessed after transplantation and during transplantation related adverse events.RESULTS: Veno-occlusive disease was accompanied by a significant increase in levels of IL-6, IL-8 and TNF-α.Graft-versus-Host disease was associated with a significant increase of IL-10, sIL-2R, IL-6 and TNF-α, depending on the respective stage or grade. Cytokine IL-6 enabled a significant differentiation between sepsis and fungemia, sepsis and viremia, and sepsis and bacteremia. Moreover, cytokine IL-8 enabled a significant differentiation between sepsis and viremia, sepsis and bacteremia, and bacteremia and viremia whereas IL-10 made a distinction between sepsis and viremia possible.CONCLUSION: The data demonstrate that proinflammatory cytokines might be putative indicators for early detection and differentiation of post-transplant adverse events and may allow prompt and adequate clinical intervention. Prospective clinical trials are needed to evaluate these findings.

U2 - 10.1186/s12885-015-1616-z

DO - 10.1186/s12885-015-1616-z

M3 - SCORING: Journal article

C2 - 26315105

VL - 15

SP - Art. 607

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

ER -